Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Sialyltransferase Initiates New Line of Sugar-Modifying Enzymes

By BiotechDaily International staff writers
Posted on 11 Jul 2013
The first in a line of recombinant enzymes for the in vitro sialylation of glycoproteins and other macromolecules is now available for biotech researchers.

The new product, alpha-2,6-sialyltransferase, was recently launched by Roche (Basel, Switzerland). Sialyltransferases are enzymes that transfer sialic acid to the terminal portions of sialylated glycolipids (gangliosides) or to the N- or O-linked sugar chains of glycoproteins. Each sialyltransferase is specific for a particular sugar substrate. There are about twenty different sialyltransferases, which can be distinguished on the basis of the acceptor structure on which they act and on the type of sugar linkage they form.

The Roche alpha-2,6-sialyltransferase is based on a human genome sequence and expressed in mammalian expression systems. The enzyme was produced under animal-origin free conditions and offers a very high lot-to-lot consistency. Specifications call for the enzyme to deliver up to 95% bi-antennary sialylation of N-glycan chains within six to eight hours, a performance which is currently not offered by competitor products.

Over the coming months, Roche plans to complete the portfolio through launches of additional sialyl-and galactosyltransferase enzyme products.

“This launch is the first in a series to offer a complete glyco-engineering portfolio of key enzymes and activated sugars covering a broad spectrum of applications,” said Ruedi Stoffel, head of biochemical reagents and custom biotech at Roche. “The initial feedback from bio-manufacturing customers showed that our continuous scientific and technical support throughout the up-scaling and development process differentiates Roche as a strong partner.”

Related Links:
Roche




Channels

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.